KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Payables (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Payables for 6 consecutive years, with $18.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 16.17% year-over-year to $18.1 million, compared with a TTM value of $18.1 million through Dec 2025, down 16.17%, and an annual FY2025 reading of $18.1 million, down 16.17% over the prior year.
  • Payables was $18.1 million for Q4 2025 at Recursion Pharmaceuticals, up from $13.9 million in the prior quarter.
  • Across five years, Payables topped out at $25.1 million in Q1 2025 and bottomed at $2.3 million in Q3 2024.
  • Average Payables over 5 years is $8.1 million, with a median of $4.9 million recorded in 2023.
  • The sharpest move saw Payables plummeted 54.44% in 2024, then skyrocketed 516.59% in 2025.
  • Year by year, Payables stood at $2.9 million in 2021, then surged by 60.98% to $4.7 million in 2022, then decreased by 14.71% to $4.0 million in 2023, then surged by 441.14% to $21.6 million in 2024, then fell by 16.17% to $18.1 million in 2025.
  • Business Quant data shows Payables for RXRX at $18.1 million in Q4 2025, $13.9 million in Q3 2025, and $19.3 million in Q2 2025.